Nimesulide is a recently developed analgesic, antipyretic and anti-inflammatory agent that differs from conventional nonsteroidal anti-inflammatory drugs both in structure and pharmacological profile. Since nimesulide may be prescribed for patients receiving concomitant medication, the propensity for drug interactions exists.
Major interactions involving interference with drug metabolism have not been described with Nimesulide.
A marginal decrease in plasma theophylline levels (without changes in respiratory function tests) has been described after addition of Nimesulide to chronic theophylline therapy. Nimesulide is available in the market with the dosage of 100mg.
It inhibits prostaglandin synthetase/cyclooxygenase, which limits prostaglandin production.Its cyclooxygenase inhibiting potency is intermediate, but is relatively selective for the cyclo-oxygenase-2 (COX-2) thus the potential for gastric injury and intolerance is less. It is also a free radical scavenger, and helps protect against the tissue damage that occurs during inflammation.
It is Well absorbed from GI tract following oral admin. Peak plasma levels:1-3 hours. With bid admin of 100 mg, steady-state is achieved within 24-36 hours.
Therapeutic Categories
- Analgesic, antipyretic and anti-inflammatory agent
- Non-steroidal anti-inflammatory drug, NSAID
It behaves as a competetive inhibitor of histamine release in-vivo and in-vitro, hence posseses antihistaminic and antiallergic properties.